Evidence map›Paper›PMID 37501718›Full record

ArticleFrontiers in genetics2023

Editorial: Building capacity for sickle cell disease research and healthcare.

Victoria Nembaware, Obiageli Eunice Nnodu, Raphael Zozimus Sangeda, Vivian Paintsil, Gaston Kuzamunu Mazandu, Nchangwi S Munung, Ambroise Wonkam, Arturo J Martí-Carvajal

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Victoria NembawareDivision of Human Genetics, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Obiageli Eunice NnoduCentre of Excellence for Sickle Cell Disease Research and Training (CESRTA), University of Abuja, Abuja, Nigeria.
Raphael Zozimus SangedaDepartment of Pharmaceutical Microbiology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Vivian PaintsilDirectorate of Child Health-Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Gaston Kuzamunu MazanduDivision of Human Genetics, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Nchangwi S MunungDivision of Human Genetics, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Ambroise WonkamDivision of Human Genetics, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Arturo J Martí-CarvajalCochrane Centre, Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito, Ecuador.

Funding

Sickle Pan African Research Consortium NigEria (SPARC-NEt)U01HL156942 · NHLBI · UNIVERSITY OF ABUJA · PI NNODU, OBIAGELI EUNICE · 2021 to 2025
$1.3M
NHLBI NIH HHS U01 HL156942
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Africabuilding capacityhealthcare developmentresearch infrastructureSCD knowledge advancementsickle cell disease (SCD)SickleInAfricatraining

Identifiers

PMID37501718
PMCPMC10369345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.